SAB Biotherapeutics (SABS) Earnings Date, Estimates & Call Transcripts $3.67 +0.41 (+12.58%) (As of 11/14/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SAB Biotherapeutics Latest Earnings SummaryUpcoming Earnings DateMar. 27EstimatedActual EPS (Nov. 6) -$1.12 Missed By -$0.05 Consensus EPS (Nov. 6) -$1.07 SAB Biotherapeutics posted Q3 2024 earnings on November 6, 2024, reporting an EPS of -$1.12, which missed the consensus estimate of -$1.07 by $0.05. With a trailing EPS of $0.00, SAB Biotherapeutics' earnings are expected to grow next year, from ($3.69) to ($2.97) per share. SABS Upcoming EarningsSAB Biotherapeutics' next earnings date is estimated for Thursday, March 27, 2025, based off prior year's reporting schedules. Get SAB Biotherapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSABS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SABS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad True Gold RepublicCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. SAB Biotherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.98-$0.98-$0.98Q2 20241-$1.02-$1.02-$1.02Q3 20241-$1.09-$1.09-$1.09Q4 20242-$1.30-$1.12-$1.21FY 20245($4.39)($4.21)($4.30) SAB Biotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 3/27/2025(Estimated)------- 11/6/2024--$1.07-$1.12 -$0.05-$1.12$0.50M-8/8/2024--$1.13-$0.79+$0.34-$0.79-$0.26M5/20/2024Q1 2024-$0.98-$0.54+$0.44-$0.54-$0.95M11/13/2023Q3 2023-$0.10-$0.10--$0.10-$1.27M8/21/2023Q2 2023-$0.14-$0.14--$0.14-$0.09M5/16/2023Q1 2023-$0.08-$0.15 -$0.07-$0.15$5.56M$0.58M Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2022Q3 2022-$0.14-$0.16 -$0.02-$0.16-$3.59M SAB Biotherapeutics Earnings - Frequently Asked Questions When is SAB Biotherapeutics's earnings date? SAB Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based off last year's report dates. Learn more on SABS's earnings history. Did SAB Biotherapeutics beat their earnings estimates last quarter? In the previous quarter, SAB Biotherapeutics (NASDAQ:SABS) missed the analysts' consensus estimate of ($1.07) by $0.05 with a reported earnings per share (EPS) of ($1.12). Learn more on analysts' earnings estimate vs. SABS's actual earnings. How much revenue does SAB Biotherapeutics generate each year? SAB Biotherapeutics (NASDAQ:SABS) has a recorded annual revenue of $2.24 million. How much profit does SAB Biotherapeutics generate each year? SAB Biotherapeutics (NASDAQ:SABS) has a recorded net income of -$42.19 million. SABS has generated $0.00 earnings per share over the last four quarters. What is SAB Biotherapeutics's EPS forecast for next year? SAB Biotherapeutics's earnings are expected to grow from ($3.69) per share to ($2.97) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Verastem Earnings Regulus Therapeutics Earnings Agenus Earnings Fortress Biotech Earnings Curis Earnings Bolt Biotherapeutics Earnings Molecular Templates Earnings Amgen Earnings Vertex Pharmaceuticals Earnings Gilead Sciences Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. This page (NASDAQ:SABS) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
